Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 1

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-05-31

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators study aims to test the correlation between the CoaguChek point-of-care testing (POCT) device (Roche, Switzerland) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC; rivaroxaban, apixaban and dabigatran) and to determine the diagnostic accuracy of POCT to rule out or detect relevant levels of DOAC in real-life stroke patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2

NCT02371070

Anticoagulation With Direct Oral Anticoagulants

COMPLETED

Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended

NCT04679298

Anticoagulation With Direct Oral Anticoagulants

UNKNOWN

Specific PoC Testing of Coagulation in Patients Treated With DOAC 1

NCT02825394

Anticoagulation With NOAC

UNKNOWN

Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study

NCT01704053

Clot Formation and Platelet Aggregation in Point of Care Testing

COMPLETED

In Vitro Diagnostic Test for DOAC in Urine

NCT03182829

Anticoagulant Therapy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anticoagulation With Direct Oral Anticoagulants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rivaroxaban

N=20

No interventions assigned to this group

Apixaban

N=20

No interventions assigned to this group

Dabigatran

N=20

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Stroke patients, who were newly started on oral anticoagulation with rivaroxaban, apixaban or dabigatran for secondary prevention of thromboembolic events
* Age ≥ 18 years

Exclusion Criteria

* Vitamin K antagonists or direct oral anticoagulants ≤ 14 days prior to study participation
* Low-molecular weight heparin ≤ 24 hours
* Unfractionated heparin ≤ 12 hours
* Abnormal coagulation values at baseline (Quick \< 70% or activated thromboplastin time (aPTT) \> 40sec.)
* History of coagulopathy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No